Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.
van Loevezijn AA, van der Noordaa MEM, van Werkhoven ED, Loo CE, Winter-Warnars GAO, Wiersma T, van de Vijver KK, Groen EJ, Blanken-Peeters CFJM, Zonneveld BJGL, Sonke GS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van der noordaa mem. Ann Surg Oncol. 2021 Jun;28(6):3243-3253. doi: 10.1245/s10434-020-09273-0. Epub 2020 Dec 2. Ann Surg Oncol. 2021. PMID: 33263830 Free PMC article.
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer.
Groen EJ, van der Noordaa MEM, Schaapveld M, Sonke GS, Mann RM, van Ramshorst MS, Lips EH, Vrancken Peeters MTFD, van Duijnhoven FH, Wesseling J. Groen EJ, et al. Among authors: van der noordaa mem. Breast Cancer Res Treat. 2021 Aug;189(1):213-224. doi: 10.1007/s10549-021-06235-2. Epub 2021 May 4. Breast Cancer Res Treat. 2021. PMID: 33945043 Free PMC article.
Breast-Conserving Therapy in Patients with cT3 Breast Cancer with Good Response to Neoadjuvant Systemic Therapy Results in Excellent Local Control: A Comprehensive Cancer Center Experience.
van der Noordaa MEM, Ioan I, Rutgers EJ, van Werkhoven E, Loo CE, Voorthuis R, Wesseling J, van Urk J, Wiersma T, Dezentje V, Vrancken Peeters MTFD, van Duijnhoven FH. van der Noordaa MEM, et al. Ann Surg Oncol. 2021 Nov;28(12):7383-7394. doi: 10.1245/s10434-021-09865-4. Epub 2021 May 12. Ann Surg Oncol. 2021. PMID: 33978889
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.
van Loevezijn AA, van der Noordaa MEM, Stokkel MPM, van Werkhoven ED, Groen EJ, Loo CE, Elkhuizen PHM, Sonke GS, Russell NS, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van der noordaa mem. Breast Cancer Res Treat. 2022 May;193(1):37-48. doi: 10.1007/s10549-022-06545-z. Epub 2022 Mar 3. Breast Cancer Res Treat. 2022. PMID: 35239072 Free PMC article.
Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
van der Noordaa MEM, van Duijnhoven FH, Loo CE, van Werkhoven E, van de Vijver KK, Wiersma T, Winter-Warnars HAO, Sonke GS, Vrancken Peeters MTFD. van der Noordaa MEM, et al. Breast. 2018 Aug;40:76-81. doi: 10.1016/j.breast.2018.04.015. Epub 2018 May 22. Breast. 2018. PMID: 29698928
[18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy.
van Loevezijn AA, Stokkel MPM, Donswijk ML, van Werkhoven ED, van der Noordaa MEM, van Duijnhoven FH, Vrancken Peeters MTFD. van Loevezijn AA, et al. Among authors: van der noordaa mem. EJNMMI Res. 2021 Aug 21;11(1):78. doi: 10.1186/s13550-021-00824-4. EJNMMI Res. 2021. PMID: 34417932 Free PMC article.
15 results